Aseptic Fill Finish
ARTICLES
-
![GettyImages-2176475661 tabet press, pharma manufacturing]( "Two Decades, One Focus: Sterile Manufacturing Excellence")
Two Decades, One Focus: Sterile Manufacturing ExcellenceDiscover expert aseptic manufacturing with flexible batch sizes, regulatory excellence, and end-to-end support, specializing in sterile injectable solutions for clinical and commercial needs.
-
OSO Biopharmaceuticals Capabilities Overview
OSOBio is a contract manufacturing organization (CMO) that focuses on biologic and pharmaceutical injectable finished drug products- (sterile liquid, liquid suspension and lyophilized formulations)
SUPPLIER PROFILES
-
Integrity Bio
Provide help to those who strive to save or improve the quality of human life by providing them the integrated services of Formulation Development, GMP Fill Finish Services, and Innovative Drug Delivery technologies.
-
Haupt Pharma AG
With nine sites in Germany, Italy, France and Japan, and a representative office in the U.S., Haupt Pharma is one of the largest European companies for pharmaceutical contract development and manufacturing.
-
Kemwell Biopharma
With manufacturing locations in Bangalore India, and Uppsala Sweden, Kemwell offers the entire value chain from early & late stage drug development services, clinical trial supply support, to commercial contract drug manufacturing.
-
Laureate Pharma
Laureate Biopharma is a leader in biopharmaceutical contract development and manufacturing. Our scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins.
-
Lyophilization Technology, Inc.
Lyophilization Technology provides an extensive range of scientific services and technical support for development and production of pharmaceuticals, biologics, diagnostics, biopharmaceuticals, and medical devices.
SERVICES
-
Sterile Dosage Forms
DSM manufactures sterile dosage form pharmaceuticals, comprising aseptic liquid filling, cytotoxic formulation and filling, and lyophilization.
-
Lyophilization / Potent And Cytotoxic Compounds
As a first adopter of new international cross-containment guidelines recommended by ISPE (Risk-MaPP), OsoBio expertly manages the risks posed by potent and cytotoxic compounds and DEA scheduled substances, successfully balancing the need for product quality and operator safety.
NEWS
-
OsoBio Appoints Dr. Paul W. Stoker Director Of Laboratories2/24/2014
As part of the company’s quality control department, the laboratories are responsible for testing the in-process and finished products – as well as raw materials and components – involved in OsoBio’s cGMP sterile manufacturing operations. The labs also are charged with environmental monitoring and analytical method development.
“While continuous quality compliance is key to OsoBio’s business success, it’s even more important to the patients who rely upon the medications we manufacture – and we try to never lose sight of that fact,” said Milton Boyer, president of OsoBio. “Paul will lead a team of scientists who are knowledgeable, capable and highly committed to integrity – delivering excellence to both our clients and the patients we collectively serve.”